---
title: New acting CEO and Chairperson of the Board of Directors
description: team CEO
---

Moss, 29 April 2024

The board of directors today appointed Mr. Njaal Kind as acting CEO of Gentian Diagnostics ASA. Mr. Kind joined Gentian in January 2018 as CFO. More recently he has been promoted to CFO/COO. During these years at Gentian, Mr. Kind has significantly contributed to the outstanding financial performance of the company. As acting CEO, Mr. Kind will also continue to serve as CFO and COO.   
The company’s general meeting has resolved to elect Ms. Hilja Ibert as chairperson of the board of directors. Ms. Ibert has therefore resigned as CEO effective today.

“It has been a pleasure to serve Gentian Diagnostics as CEO since July 2018. I am impressed what the Gentian team has achieved during that period, in which sales has resulted in a compounded annual growth rate of 30%. With my transition to a board position, I am still committed to securing further profitable growth and development of the company. Gentian is now in safe hands with Njaal Kind as acting CEO. He is known and trusted by our stakeholders, and I am confident that he will solve this mission in an excellent manner.”

 

IR contact:

Njaal Kind, CEO

njaal.kind@gentian.no

+47 919 06 525 (mobile)

 

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/new-acting-ceo-and-chairperson-of-the-board-of-directors#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/new-acting-ceo-and-chairperson-of-the-board-of-directors#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/new-acting-ceo-and-chairperson-of-the-board-of-directors#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)